about
How much human milk do infants consume? Data from 12 countries using a standardized stable isotope methodology.Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.Objectively measured physical activity and fat mass in children: a bias-adjusted meta-analysis of prospective studies.Dietary energy density and adiposity: employing bias adjustments in a meta-analysis of prospective studies.A proposed method of bias adjustment for meta-analyses of published observational studies.Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial.Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish.Genetic predisposition to type 2 diabetes is associated with impaired insulin secretion but does not modify insulin resistance or secretion in response to an intervention to lower dietary saturated fat.Moderate ingestion of alcohol is associated with acute ethanol-induced suppression of circulating CTX in a PTH-independent fashion.Diet and glycosylated haemoglobin in the 1946 British birth cohort.Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administrationAdaptive designs for dual-agent phase I dose-escalation studies.An adaptive design for updating the threshold value of a continuous biomarker.A product of independent beta probabilities dose escalation design for dual-agent phase I trials.Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.Acute effects of hyperglycaemia on asymmetric dimethylarginine (ADMA), adiponectin and inflammatory markers (IL-6, hs-CRP) in overweight and obese women with metabolic syndrome.A phase 2 study of vatalanib in metastatic melanoma patients.Escalation strategies for combination therapy Phase I trials.Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis.Variation in the urokinase-plasminogen activator gene does not explain the chromosome 10 linkage signal for late onset AD.Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points.Multiple sclerosis recurrence risk for siblings in an isolated population of Central Sardinia, ItalyAdmissible multiarm stepped-wedge cluster randomized trial designsA prospective analysis of dietary energy density at age 5 and 7 years and fatness at 9 years among UK childrenIs sugar-sweetened beverage consumption associated with increased fatness in children?Sample size re-estimation in crossover trials: application to the AIM HY-INFORM studyDesigning and evaluating dose-escalation studies made easy: The MoDEsT web appA Review of Perspectives on the Use of Randomization in Phase II Oncology Trials
P50
Q33730101-602B6C52-C677-4ED8-830B-29C390200478Q33772533-BA21AD27-D086-444D-84EC-AB58629F462BQ33839287-A18B9AC5-DE46-46DE-81FC-617BBD07DA99Q34573727-24AE52A4-7FE1-413E-B485-582DBB95A53EQ35137942-240BE8C4-9782-4C2C-92F9-BABD6534536FQ35515066-7419AABD-5CBC-4746-8B0D-FF0AB87DD117Q36231619-D0F51157-FB50-4F3E-8D0D-864C6A96D9EEQ36250132-9AD73B16-6DCE-42AB-83F0-A3203C1FE2B1Q37283783-57C9233A-D50B-47B6-8C21-BF0259C31582Q37380893-F00692EF-1658-47B7-A223-D38D428248D5Q37505622-DC39C436-E12D-45EC-B0A9-B2F36AA21F54Q38090897-058A4222-66E5-4A7A-ACD5-76A5091C2A0AQ39601160-9A44781D-D535-478F-8567-4B0BBF9A7C69Q39958094-3C3842C6-4F8C-45A8-AC91-29EA3BD761B9Q42141287-1490A639-7973-45E9-A73F-B937090C83B3Q42752477-E694C057-01C2-4D5A-907B-290FF9F74DCBQ42923862-68C6527C-598F-4361-8833-A7E2C5BBDAF3Q43246672-25636E79-2754-4B7C-AEC2-0BB497E1610AQ44029244-41648080-98AE-448F-BF03-73F410E64B9CQ47312528-4F75F073-A2A2-4A2B-B027-261660D556D6Q51612789-FA588633-8688-406D-8720-EA4E1D44F4BEQ57268393-DC3B3BEF-A8FD-4671-BD13-D833F088FBEDQ58608961-862EBB00-2C60-4C47-AAE9-813BE56B1414Q59545922-551F5BCC-D5DC-4C25-A4C3-518632AABD70Q59545924-C93DECF8-12DA-4424-B9E7-A9AD97A8023BQ91612335-4451FC83-F2FF-436E-B354-3DB964D4B7C7Q92126983-6B958988-E250-4517-8FCC-1DD3FA87E808Q92890383-695BA6A8-9E81-4895-AC3E-8B45B20176C3
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-0742-9040
@en
name
Adrian Mander
@ast
Adrian Mander
@en
Adrian Mander
@es
Adrian Mander
@nl
type
label
Adrian Mander
@ast
Adrian Mander
@en
Adrian Mander
@es
Adrian Mander
@nl
prefLabel
Adrian Mander
@ast
Adrian Mander
@en
Adrian Mander
@es
Adrian Mander
@nl
P106
P31
P496
0000-0002-0742-9040